These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30635088)

  • 21. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade.
    Chiti F; Dobson CM
    Annu Rev Biochem; 2017 Jun; 86():27-68. PubMed ID: 28498720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Hsp70 in age-related diseases and the prevention of cancer.
    Pierpaoli EV
    Ann N Y Acad Sci; 2005 Dec; 1057():206-19. PubMed ID: 16399896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.
    Aigelsreiter A; Janig E; Stumptner C; Fuchsbichler A; Zatloukal K; Denk H
    Pathobiology; 2007; 74(3):145-58. PubMed ID: 17643060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic Diseases Drug Discovery World Summit--SRI conference. Diabetes and obesity. 28-29 July 2003 San Diego, CA, USA.
    Xu J
    IDrugs; 2003 Sep; 6(9):850-1. PubMed ID: 14565170
    [No Abstract]   [Full Text] [Related]  

  • 25. Molecular chaperones biochemistry and role in neurodegenerative diseases.
    Chaari A
    Int J Biol Macromol; 2019 Jun; 131():396-411. PubMed ID: 30853582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular chaperones: toward new therapeutic tools.
    Almeida MB; do Nascimento JL; Herculano AM; Crespo-López ME
    Biomed Pharmacother; 2011 Jul; 65(4):239-43. PubMed ID: 21737228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for the inhibition of protein aggregation in human diseases.
    Bartolini M; Andrisano V
    Chembiochem; 2010 May; 11(8):1018-35. PubMed ID: 20401887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the endocannabinoid system: to enhance or reduce?
    Di Marzo V
    Nat Rev Drug Discov; 2008 May; 7(5):438-55. PubMed ID: 18446159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visiting the ER: the endoplasmic reticulum as a target for therapeutics in traffic related diseases.
    Aridor M
    Adv Drug Deliv Rev; 2007 Aug; 59(8):759-81. PubMed ID: 17681635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of protein structure instability: from physiological to pathological secondary structure.
    Sukhanova A; Poly S; Shemetov A; Bronstein I; Nabiev I
    Biopolymers; 2012 Aug; 97(8):577-88. PubMed ID: 22605549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The attention of researchers on the biological process of protein folding has turned to the formation and properties of aggregates.
    Ellis RJ
    Semin Cell Dev Biol; 2004 Feb; 15(1):1-2. PubMed ID: 15036201
    [No Abstract]   [Full Text] [Related]  

  • 32. Designed multiple ligands in metabolic disease research: from concept to platform.
    Gattrell W; Johnstone C; Patel S; Smith CS; Scheel A; Schindler M
    Drug Discov Today; 2013 Aug; 18(15-16):692-6. PubMed ID: 23454344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders.
    Bose S; Cho J
    Ageing Res Rev; 2017 May; 35():155-175. PubMed ID: 27702699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic Diseases Drug Discovery World Summit.
    Liu G
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):577-82. PubMed ID: 14662006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological chaperones: potential treatment for conformational diseases.
    Bernier V; Lagacé M; Bichet DG; Bouvier M
    Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unfolding retinal dystrophies: a role for molecular chaperones?
    Chapple JP; Grayson C; Hardcastle AJ; Saliba RS; van der Spuy J; Cheetham ME
    Trends Mol Med; 2001 Sep; 7(9):414-21. PubMed ID: 11530337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GPR120 agonism as a countermeasure against metabolic diseases.
    Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
    Drug Discov Today; 2014 May; 19(5):670-9. PubMed ID: 24315954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse Diseases.
    Kamal MA; Greig NH
    Curr Pharm Des; 2017; 23(11):1571-1574. PubMed ID: 28701141
    [No Abstract]   [Full Text] [Related]  

  • 39. Sirtuin modulators: targets for metabolic diseases and beyond.
    Szczepankiewicz BG; Ng PY
    Curr Top Med Chem; 2008; 8(17):1533-44. PubMed ID: 19075764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials.
    Colabufo NA; Berardi F; Cantore M; Contino M; Inglese C; Niso M; Perrone R
    J Med Chem; 2010 Mar; 53(5):1883-97. PubMed ID: 19924994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.